MedTrace Logo

Effectiveness of NEURAPAS Balance in Children With Nervous Restlessness

NCT01125579 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 115

Last updated 2021-09-21

No results posted yet for this study

Summary

Purpose: To document data on effectiveness of NEURAPAS® balance (NPB) in the treatment of nervous restlessness in children aged 6 to 12.

Each patient is treated with NPB. No placebo group is established. Course and severity of symptoms is documented by a questionnaire on 13 common symptoms of nervous restlessness and a Visual Analogue Scale (VAS). A standardized questionnaire (Parent Child Behaviour Checklist (CBCL/4-18)) is completed. Choice and doses of therapy are at the respective physician's discretion. The planned treatment and observation period is 2 - 4 weeks.

Conditions

  • Nervousness
  • Restlessness
  • Depression (Agitated)
  • Affective Disorders

Sponsors & Collaborators

  • Pascoe Pharmazeutische Praeparate GmbH

    lead INDUSTRY

Principal Investigators

  • Anja Braschoss, MD · Pascoe Pharmazeutische Praeparate GmbH

Eligibility

Min Age
6 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01125579 on ClinicalTrials.gov